Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) have been given an average rating of "Moderate Buy" by the thirteen analysts that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $11.00.
A number of brokerages have recently commented on AMLX. Leerink Partnrs upgraded shares of Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 6th. Wall Street Zen cut shares of Amylyx Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. Leerink Partners upgraded shares of Amylyx Pharmaceuticals from a "market perform" rating to an "outperform" rating and boosted their target price for the company from $4.00 to $10.00 in a report on Wednesday, May 7th. Guggenheim began coverage on shares of Amylyx Pharmaceuticals in a report on Tuesday, June 24th. They set a "buy" rating and a $17.00 target price on the stock. Finally, HC Wainwright boosted their target price on shares of Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the company a "buy" rating in a report on Friday, May 9th.
Check Out Our Latest Stock Analysis on Amylyx Pharmaceuticals
Hedge Funds Weigh In On Amylyx Pharmaceuticals
A number of hedge funds have recently bought and sold shares of the company. Valeo Financial Advisors LLC purchased a new position in Amylyx Pharmaceuticals in the 1st quarter worth about $35,000. Alpine Global Management LLC purchased a new position in Amylyx Pharmaceuticals in the 4th quarter worth about $45,000. Fox Run Management L.L.C. purchased a new position in Amylyx Pharmaceuticals in the 4th quarter worth about $45,000. R Squared Ltd raised its position in Amylyx Pharmaceuticals by 99.9% in the 1st quarter. R Squared Ltd now owns 12,736 shares of the company's stock worth $45,000 after buying an additional 6,366 shares during the last quarter. Finally, RPO LLC purchased a new position in Amylyx Pharmaceuticals in the 4th quarter worth about $46,000. Institutional investors own 95.84% of the company's stock.
Amylyx Pharmaceuticals Price Performance
Amylyx Pharmaceuticals stock traded up $0.26 during mid-day trading on Wednesday, reaching $7.24. 1,998,819 shares of the company traded hands, compared to its average volume of 1,208,089. The firm's 50 day moving average price is $5.39 and its 200 day moving average price is $4.29. The firm has a market capitalization of $645.37 million, a price-to-earnings ratio of -2.33 and a beta of -0.49. Amylyx Pharmaceuticals has a 52-week low of $1.62 and a 52-week high of $7.39.
Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.03. On average, sell-side analysts anticipate that Amylyx Pharmaceuticals will post -2.2 EPS for the current year.
About Amylyx Pharmaceuticals
(
Get Free ReportAmylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.
See Also

Before you consider Amylyx Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amylyx Pharmaceuticals wasn't on the list.
While Amylyx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.